Literature DB >> 29959023

Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples.

François M J Lamoury1, Behzad Hajarizadeh1, Angelica Soker1, Danica Martinez1, Camelia Quek1, Philip Cunningham2, Beth Catlett2, Gavin Cloherty3, Philippa Marks1, Janaki Amin4, Jason Grebely1, Gregory J Dore1, Tanya L Applegate5.   

Abstract

Simplified, affordable tools to diagnose active hepatitis C virus (HCV) infection are needed to scale up treatment. This study evaluated the analytical performance of HCV core antigen (HCVcAg) detection in samples of plasma and dried venous blood spots (DBSs). Paired plasma and DBS samples were prepared from remnant diagnostic samples, and plasma HCV RNA and HCVcAg were quantified. Sensitivity and specificity for HCVcAg (>3 fmol/L) at two HCV RNA thresholds (≥15 and ≥3000 IU/mL) were calculated. Of 120 paired samples tested, 25 had nonquantifiable HCV RNA and 95 had quantifiable HCV RNA. The median HCV RNA level in plasma was 5.6 log10 IU/mL (interquartile range: 5.2 to 6.2). The median HCVcAg levels in plasma and DBS samples were 2.3 log10 fmol/L (interquartile range: 0.1 to 3.1) and 1.1 log10 fmol/L (interquartile range: 0.0 to 1.9), respectively. For diagnosing HCV RNA ≥3000 IU/mL, the sensitivity and specificity of HCVcAg in plasma were 97.7% (95% CI, 91%-100%) and 100% (95% CI, 87%-100%), respectively. The sensitivity and specificity of HCVcAg in DBS were 88.6% (95% CI, 80%-94%) and 97% (95% CI, 82%-100%), respectively. The data from this study demonstrate good sensitivity and specificity of HCVcAg in plasma at an HCV RNA threshold of ≥3000 IU/mL. The level of HCVcAg quantified in plasma was higher than that in DBS.
Copyright © 2018 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29959023     DOI: 10.1016/j.jmoldx.2018.05.010

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  6 in total

1.  Resistant-Associated Substitutions Do Not Affect HCV RNA and HCV Core Antigen Clearance During Direct-Acting Antiviral Agent Treatment in a Real-World Setting.

Authors:  Hongyu Chen; Jianxiang Liu; Qian Kang; Hao Luo; Ning Tan; Jiali Pan; Yuqing Yang; Min Yu; Dan Liu; Hongli Xi; Yifan Han; Ran Cheng; Yanyan Yu; Xiaoyuan Xu
Journal:  Infect Drug Resist       Date:  2022-06-28       Impact factor: 4.177

2.  Hepatitis C Core-Antigen Testing from Dried Blood Spots.

Authors:  Mia J Biondi; Marjolein van Tilborg; David Smookler; Gregory Heymann; Analiza Aquino; Stephen Perusini; Erin Mandel; Robert A Kozak; Vera Cherepanov; Matthew Kowgier; Bettina Hansen; Lee W Goneau; Harry L A Janssen; Tony Mazzulli; Gavin Cloherty; Robert J de Knegt; Jordan J Feld
Journal:  Viruses       Date:  2019-09-06       Impact factor: 5.048

Review 3.  Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men.

Authors:  Bernadien M Nijmeijer; Jelle Koopsen; Janke Schinkel; Maria Prins; Teunis Bh Geijtenbeek
Journal:  J Int AIDS Soc       Date:  2019-08       Impact factor: 5.396

4.  Diverse HCV Strains And HIV URFS Identified Amongst People Who Inject Drugs In India.

Authors:  Mary A Rodgers; Selvamurthi Gomathi; Ana Vallari; Shanmugam Saravanan; Gregory M Lucas; Shruti Mehta; Sunil S Solomon; Gavin A Cloherty
Journal:  Sci Rep       Date:  2020-04-29       Impact factor: 4.379

5.  Performance of HCV Antigen Testing for the Diagnosis and Monitoring of Antiviral Treatment: A Systematic Review and Meta-Analysis.

Authors:  Geane Lopes Flores; Jurema Corrêa Mota; Larissa Tropiano da Silva Andrade; Renata Serrano Lopes; Francisco Inácio Bastos; Livia Melo Villar
Journal:  Biomed Res Int       Date:  2022-01-04       Impact factor: 3.411

6.  Evaluation of hepatitis C virus antibody assay using dried blood spot samples.

Authors:  Vera Holzmayer; Russell Taylor; Mary C Kuhns; Susan H Gawel; Nicaise Ndembi; Dora Mbanya; Lazare Kaptue; Mary A Rodgers; Gavin Cloherty
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.